Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2015

View Archived Issues

Met inhibition shows promising preclinical results for the treatment of nasopharyngeal carcinoma

ONCOS-102 receives FDA orphan drug status for malignant mesothelioma

Palatin initiates phase III program for bremelanotide in female sexual dysfunction

FDA grants orphan drug and rare pediatric disease designations to entrectinib for neuroblastoma

AMAG and Takeda terminate ex-U.S. ferumoxytol agreement

Repros initiates phase IIb studies of Proellex for uterine fibroids

Lilly begins phase I study of LY-3202626 in healthy subjects and Alzheimer's patients

Nippon Zoki and AnGes cancel licensing agreement

Neuren provides update on the development of NNZ-2566

Idera Pharmaceuticals provides update on IMO-8400 in Waldenstrom's macroglobulinemia

NeuroDerm reports topline results from phase IIa study of ND-0612H and ND-0612L

OncoGenex to regain rights to custirsen from Teva Pharmaceutical

Aquinox initiates phase II study of AQX-1125 for atopic dermatitis

Vaccines for Gram-negative infections described in EIT+ patent

Shanghai Institute Materia Medica patents novel RTK inhibitors

MAGL inhibitor evaluated in a mouse model of ALS

Anti-CD47 MAb demonstrate efficacy in animal models of leukemia/lymphoma

Preclinical data presented on BBI-11008 for the treatment of L-DOPA-induced dyskinesia

Investigators in Barcelona prepare and test tyrosine-protein kinase inhibitors

Asceneuron synthesizes M1 receptor PAMs

Cathepsin D inhibitors in early development at Merck KGaA

Ampla Pharmaceuticals describes GPBAR1 agonists

Roche reports cannabinoid CB2 receptor agonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...